logo

Financials

Navigation Toggle
v3.26.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Apr. 30, 2026
Apr. 30, 2025
Current assets:    
Cash and cash equivalents $ 18,603,899 $ 15,172,163
Marketable equity securities 254,010 366,316
Dividends receivable 240,766 0
Investment in preferred stock – QCLS - current 18,225,000 0
Warrant asset – QCLS - current 0 2,917,000
Convertible Note receivable – Femasys - current 0 3,696,000
Prepaid expenses and other current assets 96,879 223,759
Total current assets 37,420,554 22,375,238
Other assets:    
Intangible assets 0 1,549,427
Investment in preferred stock – QCLS 0 22,474,000
Warrant assets – QCLS - non current 8,845,000 5,701,000
Warrant assets – Femasys 480,000 3,061,000
Other assets 7,688 7,688
Total other assets 9,332,688 32,793,115
Total Assets 46,753,242 55,168,353
Current liabilities:    
Accounts payable 271,102 399,204
Accrued expenses 522,831 2,515,080
Accrued Series C dividends 32,491 0
Total current liabilities 826,424 2,914,284
Other liabilities:    
Long-term portion of accrued expenses 0 25,000
Warrant liability 10,068,000 338,000
Derivative liability 878,000 0
Total other liabilities 10,946,000 363,000
Total Liabilities 11,772,424 3,277,284
Commitments and Contingencies (Note 9)
Temporary Equity:    
Contingently redeemable warrants 417,000 0
Total temporary equity 1,685,892 0
Stockholders’ equity:    
Preferred stock value 0 0
Common stock, authorized: 200,000,000 shares, $0.0001 par value; 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of April 30, 2026 and April 30, 2025, respectively. 2,602 2,167
Additional paid-in capital 182,716,275 181,489,647
Accumulated deficit (104,393,614) (84,968,960)
Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of April 30, 2026, and 2025, respectively (45,009,541) (44,607,916)
Accumulated other comprehensive loss (20,796) (23,869)
Total stockholders’ equity 33,294,926 51,891,069
Total Liabilities, Temporary Equity and Stockholders’ Equity 46,753,242 55,168,353
Series B Preferred Stock [Member]    
Temporary Equity:    
Convertible preferred stock 0 0
Series C Preferred Stock [Member]    
Temporary Equity:    
Convertible preferred stock 1,268,892 0
Series A Preferred Stock [Member]    
Stockholders’ equity:    
Preferred stock value $ 0 $ 0

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Income Statement [Abstract]    
Revenue $ 0 $ 0
Operating expenses:    
Research and development costs 391,301 438,416
Intangible asset impairment 1,549,427 0
General and administrative 4,912,985 3,939,446
Total operating expenses 6,853,713 4,377,862
Loss from operations (6,853,713) (4,377,862)
Other income (expense):    
Interest income 733,351 1,415,561
Dividend income 380,682 0
Change in fair value of warrant liability (4,746,135) 10,446,000
Change in fair value of derivative liability 1,117,000 2,184,000
Change in fair value of convertible note receivable – Femasys 1,304,000 941,000
Change in fair value of warrant asset – Femasys (2,581,000) (2,091,000)
Change in fair value of investment – QCLS (7,732,000) 5,063,950
Change in fair value of warrant assets – QCLS (1,379,000) (2,367,684)
Gain on related party investment – QCLS 2,089,000 21,395,734
Gain on legal settlement – re-fair value of warrants 106,000 0
Issuance costs – Series C convertible preferred stock and warrants (1,234,553) 0
Unrealized gain (loss) on marketable securities (412,306) 66,316
Loss on legal settlement 0 (2,019,000)
Loss on issuance of Series C preferred stock (215,000) 0
Other expense, net (980) (965)
Total other income (expense), net (12,570,941) 35,033,912
Income tax benefit (expense) 0 0
Net income (loss) (19,424,654) 30,656,050
Preferred stock dividends (278,496) (1,129,759)
Undistributed income to Series B convertible preferred stock 0 (2,970,780)
Preferred stock accretion (3,503,222) (3,193,404)
Net income (loss) attributable to common stockholders $ (23,206,372) $ 23,362,107
Basic income (loss) per share attributable to common stockholders $ (2.77) $ 3.19
Diluted income (loss) per share attributable to common stockholders $ (2.77) $ 3.19
Weighted average shares outstanding basic 8,378,291 7,329,596
Weighted average shares outstanding diluted 8,378,291 7,329,596

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL
v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Cash flows from operating activities:    
Net income (loss) $ (19,424,654) $ 30,656,050
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on related party investment - QCLS (2,089,000) (21,395,734)
Issuance costs – Series C preferred stock and warrants 1,234,553 0
Loss on issuance of Series C preferred stock 215,000 0
Gain on re-fair value of warrants (106,000) 0
Non-cash interest income (162,500) (300,000)
Non-cash warrant liability 0 469,000
Intangible asset impairment 1,549,427 0
Stock issued for compensation - RSUs 892,500 0
Stock-based compensation - options 236,056 478,637
Unrealized (gain) loss on marketable equity securities 412,306 (66,316)
Change in fair value of warrant liability 4,746,135 (10,446,000)
Change in fair value of derivative liability (1,117,000) (2,184,000)
Change in fair value of convertible note receivable - Femasys (1,304,000) (941,000)
Change in fair value of warrant assets - Femasys 2,581,000 2,091,000
Change in fair value of investment - QCLS 7,732,000 (5,063,950)
Change in fair value of warrants - QCLS 1,379,000 2,367,684
Change in assets and liabilities:    
(Increase) decrease in prepaid expenses and other current assets (251,386) 36,041
Increase (decrease) in accounts payable (128,102) 9,835
Increase (decrease) in accrued expenses (1,548,249) 1,310,457
Net cash used in operating activities (5,152,914) (2,978,296)
Cash flows from investing activities:    
Investment in preferred stock and warrants - QCLS (3,000,000) (7,000,000)
Proceeds from investment – note receivable 5,000,000 0
Net cash provided by (used in) investing activities 2,000,000 (7,000,000)
Cash flows from financing activities:    
Repurchase of common stock, net (401,625) (2,542,276)
Net proceeds from issuance of Series C preferred stock 6,182,447 0
Redemption of preferred stock 0 (22,486,875)
Payment of Series C convertible preferred stock dividends (246,005) 0
Net proceeds from warrant exercise 1,046,760 0
Net cash provided by (used in) financing activities 6,581,577 (25,029,151)
Effect of currency rate exchange on cash and cash equivalents 3,073 (358)
Net increase (decrease) in cash and cash equivalents 3,431,736 (35,007,805)
Cash and cash equivalents at beginning of the year 15,172,163 50,179,968
Cash and cash equivalents at end of the year 18,603,899 15,172,163
Supplemental disclosure of cash flows information:    
Cash paid during the year for income taxes 0 0
Supplemental schedule of non-cash investing and financing activities:    
Accrual of Series C Convertible Preferred Stock dividends 278,496 0
Accretion of discounts to redemption value of Series C Preferred Stock 3,503,222 0
Initial fair value of investment in QCLS Series H preferred shares 3,483,000 0
Initial fair value of investment in QCLS Series H warrants 1,606,000 0
Non-cash derivative liability at initial fair value 1,995,000 0
Non-cash warrant liability at initial fair value 5,220,000 0
Non-cash conversion of Series C convertible stock 2,234,330 0
Change in fair value associated warrant exercises 599,135 0
Fair value of contingently redeemable placement agent warrants 417,000 0
Series B Convertible Preferred Stock dividends 0 1,129,759
Accretion of discounts to redemption value of Series B Convertible Preferred Stock 0 3,193,404
Excise tax accrued on repurchase of common stock $ 0 $ 25,424

Source

PDF HTML
10-K Filing
ZIP XLS HTML
XBRL